Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Other Non-Current Assets: 2021-2025

Historic Other Non-Current Assets for Janux Therapeutics (JANX) over the last 4 years, with Sep 2025 value amounting to $2.6 million.

  • Janux Therapeutics' Other Non-Current Assets fell 6.94% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 6.94%. This contributed to the annual value of $2.9 million for FY2024, which is 14.95% up from last year.
  • As of Q3 2025, Janux Therapeutics' Other Non-Current Assets stood at $2.6 million, which was down 2.45% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' Other Non-Current Assets peaked at $2.9 million during Q4 2024, and registered a low of $140,000 during Q3 2021.
  • For the 3-year period, Janux Therapeutics' Other Non-Current Assets averaged around $2.5 million, with its median value being $2.6 million (2025).
  • In the last 5 years, Janux Therapeutics' Other Non-Current Assets soared by 923.57% in 2022 and then dropped by 6.94% in 2025.
  • Quarterly analysis of 5 years shows Janux Therapeutics' Other Non-Current Assets stood at $816,000 in 2021, then surged by 70.34% to $1.4 million in 2022, then skyrocketed by 80.50% to $2.5 million in 2023, then climbed by 14.95% to $2.9 million in 2024, then decreased by 6.94% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $2.7 million for Q2 2025, and $2.8 million during Q1 2025.